A novel selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer.
Chiang CY, Zhang M, Huang J, Zeng J, Chen C, Pan D, Yang H, Zhang T, Yang M, Han Q, Wang Z, Xiao T, Chen Y, Zou Y, Yin F, Li Z, Zhu L, Zheng D.
Chiang CY, et al. Among authors: yin f.
Acta Pharmacol Sin. 2024 Feb;45(2):422-435. doi: 10.1038/s41401-023-01164-w. Epub 2023 Oct 10.
Acta Pharmacol Sin. 2024.
PMID: 37816856